PTC Therapeutics signs lease with Bristol-Myers Squibb — 3 insights

PTC Therapeutics is leasing a 185,000-square-foot biologics-focused research space from Bristol-Myers Squibb, BioPharmaReport.com reports.

Advertisement

What you should know:

1. PTC entered into a 15-year lease. The space includes a biologics production facility, research spaces and operations buildings.

2. PTC will develop the biologics facility to support its gene therapy production capabilities. The site is pivoting its current production schedule to create materials to support PTC’s preclinical and clinical programs.

3. PTC also intends to relocate its research operations to the site.

More articles on biologics:
Why Dr. Dominic Thomas Kleinhenz joined University Orthopedics and the biggest obstacle in spine
Dr. Stephen Hochschuler: Future trends in spine – telemedicine, robotics, AI & more
Dr. Christopher Kager: The standout spine procedure in his career, future of biologics & more

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Biologics

Advertisement

Comments are closed.